<DOC>
	<DOCNO>NCT00463021</DOCNO>
	<brief_summary>Protocol HECT00306 aim determine clinically appropriate dos Hectorol ( doxercalciferol capsule ) convert Zemplar ( paricalcitol injection ) treatment secondary hyperparathyroidism Stage 5 chronic kidney disease hemodialysis .</brief_summary>
	<brief_title>A Phase 4 Study Determine Dosing Hectorol® Capsules When Converting From Zemplar® Injection</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>The subject must receive hemodialysis three time per week minimum six month . The subject must receive Zemplar Injection minimum 3 month . The subject must stable dose regimen , three time per week administration minimum four week . The central laboratory assessment must within follow range : serum iPTH 150600 pg/mL , inclusive ; correct calcium &lt; 10.0 mg/dL ; phosphorus &lt; 7.0 mg/dL . In opinion Investigator , subject currently poorly control diabetes mellitus , poorly control hypertension , active vasculitis , HIV infection , clinically significant , unstable medical condition . Abnormal liver function measure ALT/AST great two time upper limit normal ( ULN ) . The subject currently malabsorption , severe chronic diarrhea , ileostomy . Any evidence active malignancy except basal cell carcinoma skin . A history malignancy exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hectorol ( doxercalciferol capsule )</keyword>
	<keyword>Zemplar ( paricalcitol injection )</keyword>
</DOC>